In addition, hepatic fat accumulation can be modulated by the interaction between PNPLA3 I148M variant and dietary omega 6/omega 3 PUFAs and diet supplemented with n-3 respect to n-6 PUFA could provide a targeted therapy in NAFLD subjects who are homozygous for the PNPLA3 G allele (17). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.